Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578350 | 0.79 | MAPT (0.50) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL7361151 | 0.76 | MAPT (0.47) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL514482 | 0.76 | MAPT (0.55) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL3328543 | 0.75 | MAPT (0.79) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL223594 | 0.75 | MEN1 (0.59) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL4163474 | 0.75 | MAPT (0.79) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL10652156 | 0.75 | MAPT (0.55) | MAPTMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL27909482 | 0.74 | ALDH1A1 (0.72) | MEN1KMT2AALDH1A1HSD17B10ACHE | |
| SCHEMBL22567 | 0.74 | ALDH1A1 (0.72) | MEN1KMT2AALDH1A1HSD17B10ACHE | |
| SCHEMBL4601126 | 0.73 | TGM2 (0.51) | MAPTMEN1KMT2AALDH1A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105246904-B | Ruthenium base complex, their preparation and the purposes as catalyst | 阿朗新科德国有限责任公司 | 2018-06-01 | — | — | CN | disclosed |
| EP-3004123-B1 | RUTHENIUM-BASED COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-9920086-B2 | Ruthenium-based complexes, their preparation and use as catalysts | ARLANXEO DE GMBH (DE) | 2018-03-20 | — | — | US | disclosed |
| US-9920086-B2 | Ruthenium-based complexes, their preparation and use as catalysts | ARLANXEO DE GMBH (DE) | 2018-03-20 | — | — | US | disclosed |
| EP-3004123-A1 | RUTHENIUM-BASED COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTS | LANXESS Deutschland GmbH (DE) | 2016-04-13 | — | — | EP | disclosed |
| US-20160090396-A1 | RUTHENIUM-BASED COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2016-03-31 | — | — | US | disclosed |
| US-20160090396-A1 | RUTHENIUM-BASED COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2016-03-31 | — | — | US | disclosed |
| US-20160090396-A1 | RUTHENIUM-BASED COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2016-03-31 | — | — | US | disclosed |
| CN-105246904-A | Ruthenium-based complexes, their preparation and use as catalysts | LANXESS DEUTSCHLAND GMBH | 2016-01-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090396-A1 | RUTHENIUM-BASED COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTS | TST, VARS1, NBAS | MAPT 3888/4885MEN1 1505/4885KMT2A 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.